Use of high-dose, twice-yearly albendazole and ivermectin to suppress Wuchereria bancrofti microfilarial levels

Clinical Infectious Diseases

Volumn 51, Issue 11, 2010, Pages 1229-1235

  Dembele, Benoit ^a   Coulibaly, Yaya I ^a   Dolo, Housseini ^a   Konate, Siaka ^a   Coulibaly, Siaka Y ^a   Sanogo, Dramane ^a   Soumaoro, Lamine ^a   Coulibaly, Michel E ^a   Doumbia, Salif Seriba ^a   Diallo, Abdallah A ^a   Traore, Sekou F ^a   Keita, Adama Diaman ^b   Fay, Michael P ^c   Nutman, Thomas B ^d   Klion, Amy D ^d  

^a UNIVERSITY OF BAMAKO   (Mali)

^b Point G Hospital   (Mali)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; IVERMECTIN;

ABDOMINAL PAIN; ADULT; ANGIONEUROTIC EDEMA; ARTICLE; BANCROFTIAN FILARIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL SYMPTOM; HERNIA INCARCERATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; ULCER; URTICARIA; WUCHERERIA BANCROFTI;

ADOLESCENT; ADULT; AGED; ALBENDAZOLE; ANIMALS; DRUG THERAPY, COMBINATION; ENDEMIC DISEASES; FEMALE; FILARIASIS; FILARICIDES; HUMANS; IVERMECTIN; MALE; MALI; MIDDLE AGED; PARASITEMIA; WUCHERERIA BANCROFTI; YOUNG ADULT;

EID: 78649821020     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/657063     Document Type: Article

References (19)

1. Meeting of the International Task Force for Disease Eradication-29 October 2008. Wkly Epidemiol Rec 2009; 84:89-94.
2. Goldman AS, Guisinger VH, Aikins M, et al. National mass drug administration costs for lymphatic filariasis elimination. PLoS Negl Trop Dis 2007; 1(1):e67.
3. Addiss DG, Beach MJ, Streit TG, et al. Randomised placebo-controlled trial of ivermectin and albendazole alone and in combination for Wuchereria bacrofti microfilaraemia in Haitian children. Lancet 1997; 350:480-484.
4. Horton J, Witt C, Ottesen EA, et al. An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis. Parasitology 2000; 121(Suppl):S147-S160.
5. Cartel JL, Spiegel A, Nguyen Ngnoc L, et al. Compared efficacy or repeated annual and semi-annual doses of ivermectin and diethylcarbamazine for prevention of Wuchereria bancrofti filariasis in French Polynesia. FInal evaluation. Trop Med Parasitol 1992; 43:91-94.
6. Moulia-Pelat JP, Glaziou P, Nguyen LN, et al. Single doses of ivermectin 400 micrograms/kg: the most effective dosage in bancroftian filariasis. Southeast Asian J Trop Med Public Health 1995; 26:124-127.
7. Mand S, Marfo-Debrekyei Y, Dittrich M, et al. Animated documentation of the filaria dance sign (FDS) in bancroftian filariasis. Filaria J 2003; 2(1):3.
8. Fay MP. Confidence intervals that match Fisher's exact or Blaker's exact tests. Biostatistics 2010; 11:373-374.
9. Proschan MA, McMahon RP, Shih JH, et al. Sensitivity analysis using an imputation method for missing binary data in clinical trials. J Stat Plan Inference 2001; 96:155-165.
10. El-Setouhy M, Ramzy RM, Ahmed ES, et al. A randomized clinical trial comparing single and multi-dose combination therapy with diethylcarbamazine and albendazole for treatment of bancroftian filariasis. Am J Trop Med Hyg 2004; 70:191-196.
11. Cheun H, Lee J, Cho S, et al. Elimination of lymphatic filariasis in the Republic of Korea: an epidemiological survey of formerly endemic areas, 2002-2006. Trop Med Int Health 2009; 14:445-449.
12. Itoh M, Wu W, Sun D, et al. Confirmation of elimination of lymphatic filariasis by an IgG4 enzyme-linked immunosorbent assay with urine samples in Yongjia, Zhejiang Province and Gaoan, Jiangxi Province, People's Republic of China. Am J Trop Med Hyg 2007; 77:330-333.
13. Ramzy RM, El Setouhy M, Helmy H, et al. Effect of yearly mass drug administration with diethylcarbamazine and albendazole on bancroftian filariasis in Egypt: a comprehensive assessment. Lancet 2006; 367:992-999.
14. Ottesen EA, Duke BO, Karam M, et al. Strategies and tools for the control/elimination of lymphatic filariasis. Bull World Health Organ 1997; 75:491-503. (Pubitemid 28099975)
15. Stolk WA, De Vlas SJ, Borsboom GJJM, et al. LYMFASIM, a simulation model for predicting the impact of lymphatic filariasis control: quantification for African villages. Parasitology 2008; 135:1583-1598.
16. Michael E, Malecela-Lazaro MN, Simonsen PE, et al. Mathematic modelling and the control of lymphatic filariasis. Lancet Infect Dis 2004; 4:223-234. (Pubitemid 38407305)
17. Bockarie MJ, Tisch DJ, Kastens W, et al. Mass treatment to eliminate filariasis in Papua New Guinea. N Engl J Med 2002; 347:1841-1848.
18. Ottesen EA, Hooper PJ, Bradley M, et al. The global programme to eliminate lymphatic filariasis: health impact after 8 years. PLoS Negl Trop Dis 2008; 2:e317.
19. Asio SM, Simonsen PE, Onapa AW. Mansonella perstans: safety and efficacy of ivermectin alone, albendazole alone and the two drugs in combination. Ann Trop Med Parasitol 2009; 103:31-37.